|
|
| Short Contents | Full Contents | Other books NCBI |
|
|
AHCPR Archived reports, Put Prevention Into Practice and
Minnesota Health Technology Advisory Committee  SAMHSA/CSAT Treatment Improvement Protocols40. TIP 40. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Laura McNicholas Consensus Panel ChairM.D. Ph.D. Title page Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction A Treatment Improvement Protocol (TIP) 40 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment 1 Choke Cherry Road Rockville, MD 20857 This Treatment Improvement Protocol (TIP), Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, provides consensus - and evidence -based treatment guidance for the use of buprenorphine, a new option for the treatment of opioid addiction. The goal of this TIP is to provide physicians with information they can use to make practical and informed decisions about the use of buprenorphine to treat opioid addiction. These guidelines address the pharmacology and physiology of opioids, opioid addiction, and treatment with buprenorphine; describe patient assessment and the choice of opioid addiction treatment options; provide detailed treatment protocols for opioid withdrawal and maintenance therapy with buprenorphine; and include information on the treatment of special populations, e.g., pregnant women, adolescents, and polysubstance users. This TIP represents another step by the Center for Substance Abuse Treatment (CSAT) toward its goal of bringing national leaders together to improve substance use disorder treatment in the United States. DHHS Publication No. (SMA) 04 -3939 Printed 2004 AcknowledgmentsNumerous people contributed to the development of this TIP (see pp. ix, xi, and appendix J). This publication was produced by the American Institutes for Research The opinions expressed herein are the views of the consensus panel members and do not necessarily reflect the official position of CSAT, SAMHSA, or DHHS. No official support of or endorsement by CSAT, SAMHSA or DHHS for these opinions or for particular instruments, software, or resources described in this document are intended or should be inferred. The guidelines in this document should not be considered substitutes for individualized client care and treatment decisions. All materials appearing in this volume except those taken directly from copyrighted sources are in the public domain and may be reproduced or copied without permission from SAMHSA/CSAT or the authors. Do not reproduce or distribute this publication for a fee without specific, written authorization from SAMHSA's Office of Communications. Copies may be obtained free of charge from SAMHSA's National Clearinghouse for Alcohol and Drug Information (NCADI), (800) 729 -6686 or (301) 468 -2600; TDD (for the hearing impaired), (800) 487 -4889; or electronically through the following site: http://www.kap.samhsa.gov/products/manuals/index.htm. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04 -3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004. Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, 1 Choke Cherry Road, Rockville, MD 20857. DHHS Publication No. (SMA) 04 -3939 Printed 2004 Treatment Improvement Protocols (TIPs) are best -practice guidelines for the treatment of substance use disorders, provided as a service of the Substance Abuse and Mental Health Services Administration's (SAMHSA's) Center for Substance Abuse Treatment (CSAT). CSAT's Office of Evaluation, Scientific Analysis and Synthesis draws on the experience and knowledge of clinical, research, and administrative experts to produce the TIPs, which are distributed to a growing number of facilities and individuals across the country. As alcoholism and other substance use disorders are increasingly recognized as major problems, the audience for the TIPs is expanding beyond public and private substance use disorder treatment facilities. After selecting a topic, CSAT invites staff from pertinent Federal agencies and national organizations to a resource panel that recommends specific areas of focus as well as resources that should be considered in developing the content of the TIP. Then recommendations are communicated to a consensus panel composed of experts who have been nominated by their peers. This panel participates in a series of discussions; the information and recommendations on which they reach consensus become the foundation of the TIP. The members of each consensus panel represent substance use disorder treatment programs, hospitals, community health centers, counseling programs, criminal justice and child welfare agencies, and private practitioners. A panel chair (or cochairs) ensures that the guidelines mirror the results of the group's collaboration. A large and diverse group of experts reviews the draft document closely. The Buprenorphine Expert Panel, a distinguished group of substance abuse experts and professionals in such related fields as primary care, mental health, and social services, worked with the Consensus Panel Chair and the CSAT Division of Pharmacologic Therapies to generate new and updated changes to the subject matter for this TIP based on the field's current needs for information and guidance. Once the changes recommended by the field reviewers have been incorporated, the TIP is prepared for publication in print and online. The TIPs can be accessed via the Internet at http://www.kap.samhsa.gov/products/manuals/index.htm. The use of electronic media also means that the TIPs can be updated more easily so that they can continue to provide the field with state -of -the -art information. Although each TIP includes an evidence base for the practices its panel recommends, CSAT recognizes that the field of substance use disorder treatment is evolving continuously and that research frequently lags behind the innovations pioneered by those in the field. A major goal of each TIP is to convey "front line" information quickly but responsibly. For this reason, recommendations in the TIP are attributed either to panelists' clinical experience or to the appropriate literature. If there is research to support a particular approach, citations are provided. This TIP, Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, provides consensus - and evidence -based guidance on the use of buprenorphine, a new option for the treatment of opioid addiction. The goal of this TIP is to provide information that physicians can use to make practical and informed decisions about the use of buprenorphine to treat opioid addiction. The Guidelines address a number of topic areas related to this goal, including the physiology and pharmacology of opioids, opioid addiction, and treatment with buprenorphine; the screening and assessment of opioid addiction problems; detailed protocols for opioid addiction treatment with buprenorphine; management of special populations; and policies and procedures related to office -based opioid addiction treatment under the paradigm established by the Drug Addiction Treatment Act of 2000. This TIP represents another step by CSAT toward its goal of bringing national leaders together to improve substance use disorder treatment in the United States. Other TIPs may be ordered by contacting the National Clearinghouse for Alcohol and Drug Information (NCADI), (800) 729 -6686 or (301) 468 -2600; TDD (for the hearing impaired), (800) 487 -4889. See http://www.kap.samhsa.gov/products/manuals/index.htm. Chair
Chair
Our Nation has made great strides in recent years in achieving recovery for persons with substance use disorders. We know much more about how to deliver recovery -oriented substance abuse treatment, improve service quality, achieve desired improvements in quality -of -life outcomes, and implement needed care systems in each community in the United States. Our vision is of a life in the community for everyone. The Treatment Improvement Protocol (TIP) series promotes resilience and facilitates recovery from substance use disorders. The TIPs add to our knowledge base and provide best practice guidance to clinicians, program administrators, and payors. They are the result of careful consideration of all relevant clinical and health services research findings, demonstration experience, and implementation requirements. For each TIP topic, an expert panel of non -Federal clinical researchers, clinicians, program administrators, and patient advocates debates and discusses best practices until its members reach a consensus. The talent, dedication, and hard work that TIPs panelists and reviewers bring to this highly participatory process have bridged the gap between the promise of research and the needs of practicing clinicians and administrators. We are grateful to all who have joined with us to contribute to advances in the substance use disorder treatment field. We hope you will find many uses for the information contained in this volume and that you will join in our goal of helping all Americans with substance use disorders realize healthy, contributing lives in their communities nationwide. Charles G. Curie, M.A., A.C.S.W. Administrator Substance Abuse and Mental Health Services Administration H. Westley Clark, M.D., J.D., M.P.H., CAS, FASAM Director, Center for Substance Abuse Treatment Substance Abuse and Mental Health Services Administration |
Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office![[reg]](https://webarchive.library.unt.edu/eot2008/20090830174436im_/http://www.ncbi.nlm.nih.gov/books/bookres.fcgi/system_default/reg.gif)
(AIR) under the Center for Substance Abuse Treatment (CSAT) contract, task order number 277 -00 -6401 under the Substance Abuse and Mental Health Services Administration (SAMHSA) contract, Number 277 -99 -6400, U.S. Department of Health and Human Services (DHHS). CAPT Susanne Caviness, Ph.D., SR SURG Angel A. González, M.D., and Raymond Hylton, Jr., R.N., M.S.N., served as the CSAT Government Project Officers. Anton C. Bizzell, M.D., and Alan Trachtenberg, M.D., M.P.H., served as the CSAT Medical Editors. Christina Currier served as the CSAT TIPs Task Leader. Elizabeth F. Howell, M.D., served as the Senior Medical Editor. Wayne Brandes, D.O., M.P.H., served as the AIR Medical Editor and Project Director. Janet Carrese served as the AIR Deputy Project Director. Other AIR personnel included Susan Bratten, Senior Editor; Susan Keller, M.P.H., M.S., B.S.N., Quality Assurance Editor; and Patricia Louthian, Document Production Specialist. In addition, Center for Health Policy Studies (CHPS) Consulting staff Roy Walker, M.B.A., Kimberly Stern, M.H.A., Elly Gilbert, M.S., R.N., C.H.E.S., and Ji Kim served as the original support team for the consensus and field review panels. Writers were Margaret Boone, Ph.D.; Nancy J. Brown; Mary A. Moon; Deborah J. Schuman; Josephine Thomas, M.F.A.; and Denise L. Wright, Ph.D.